Adoptive cell transfer

BIOLOGICAL2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Sheba Medical Center

Conditions

A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of ResponseMetastatic Melanoma

Phase 2

Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

TerminatedNCT01988077

Sheba Medical CenterA Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response

Start: 2013-10-31End: 2018-10-25Updated: 2019-04-05

Unknown Phase

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

CompletedNCT01005745

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Melanoma

Start: 2009-10-20End: 2025-08-18Updated: 2025-12-19

Related Papers

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Journal for ImmunoTherapy of Cancer2025-04-016 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

384 An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy

Regular and Young Investigator Award Abstracts2021-11-01

385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)

Regular and Young Investigator Award Abstracts2021-11-01